ChromaDex TV Ads Increase Sales, Customer Base
Tru Niagen sales made up more than 85% of first-quarter total, and TV ads launched in March drove a “dramatic increase” in customers, says CEO Robert Fried.
You may also be interested in...
Firm emphasizes TV advertising spending and Walmart-related commercial launching in March in its earnings briefing. “We could go much broader than just sort of a male fitness sports-related cohort. We think it's a much broader-based market than that,” says CEO Robert Fried.
ChromaDex completed its phase I clinical trial studying the effects ofon Parkinson’s Disease. Lead researcher Charalampos Tzoulis is “very excited about these results” and that the trial represents “a novel approach in experimental PD-therapy.”
Tru Niagen products available at 3,800 US Walmart stores include a lower dose, 100 mg, that ChromaDex didn't previously market. Launch sparks heavy trading driving up firm's share price.